Your browser doesn't support javascript.
loading
Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
Rytelewski, Mateusz; Maleki Vareki, Saman; Mangala, Lingegowda S; Romanow, Larissa; Jiang, Dahai; Pradeep, Sunila; Rodriguez-Aguayo, Christian; Lopez-Berestein, Gabriel; Figueredo, Rene; Ferguson, Peter J; Vincent, Mark; Sood, Anil K; Koropatnick, James D.
Afiliação
  • Rytelewski M; Department of Microbiology and Immunology, Western University, London, ON, Canada.
  • Maleki Vareki S; Lawson Health Research Institute, London, ON, Canada.
  • Mangala LS; Lawson Health Research Institute, London, ON, Canada.
  • Romanow L; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jiang D; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pradeep S; Department of Microbiology and Immunology, Western University, London, ON, Canada.
  • Rodriguez-Aguayo C; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lopez-Berestein G; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Figueredo R; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ferguson PJ; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vincent M; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sood AK; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Koropatnick JD; Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oncotarget ; 7(15): 20825-39, 2016 Apr 12.
Article em En | MEDLINE | ID: mdl-26959114
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Resistencia a Medicamentos Antineoplásicos / Proteína BRCA2 / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Resistencia a Medicamentos Antineoplásicos / Proteína BRCA2 / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Canadá